Helius Therapeutics Launches Two GMP-Certified Medicinal Cannabis Products in New Zealand

Dec.30.2022
Helius Therapeutics Launches Two GMP-Certified Medicinal Cannabis Products in New Zealand
New Zealand company Helius is producing four GMP-certified medicinal cannabis products and plans to export to Europe in 2023.

In New Zealand, two new medicinal cannabis products have been confirmed to meet sales quality standards. Earlier, Helius became the first New Zealand company to receive GMP certification, producing tetrahydrocannabinol extracts and manufacturing medicines containing tetrahydrocannabinol.


Carmen Doran, Chief Executive of Helius Therapeutics, has expressed delight in bringing more medicinal cannabis products that are grown and manufactured in New Zealand to patients. The company will launch two new drugs in the New Zealand market, bringing the total number of new drugs to be launched by Helius in 2022 to four. This means that the company's product portfolio now comprises six products, according to an email sent to Vapor Voice.


In mid-December, we were able to announce GACP certification, and since then, we have also obtained GMP certification for an additional four processes in our East Auckland factory. This progress demonstrates the collaborative culture being established by the Helius team," she said.


Helius is the only company in New Zealand that has received GMP certification for the extraction and manufacturing of CBD and THC drugs. Moreover, it is now one of two companies in the country that has six products that have been verified to meet the minimum quality standards (the other being Nubu Pharma).


The latest product will be exported to Helius clients in Europe in 2023.


Products containing THC have attracted great interest internationally, with GMP-manufactured products gaining widespread attention worldwide as the medical market continues to grow. "We are particularly interested in a balanced full-spectrum medicinal cannabis formula," said Doran.


With the launch of these products, New Zealand patients now have access to a range of locally manufactured oral liquid products. They will no longer have to rely on imported products that may experience supply delays throughout 2022 and may come at a much higher cost.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

PMI Plans $71 Million Philippine Smoke-Free Expansion: BLENDS Production Established, Batangas Plant Exports to 18 Markets
PMI Plans $71 Million Philippine Smoke-Free Expansion: BLENDS Production Established, Batangas Plant Exports to 18 Markets
Philip Morris International (PMI) plans to invest approximately PHP 4.5 billion ($71 million) to expand its existing smoke-free manufacturing facility in Tanauan, Batangas, in the Philippines. The expansion is expected to be completed in 2027, with additional capacity serving domestic and export markets. The facility began manufacturing heated tobacco consumables in April 2024, including BLENDS sticks for the BONDS by IQOS platform. Philippine business media reported in October 2026 that products from the Batangas plant were being exported to 18 markets across Asia and Europe. PMI says it has invested more than $2 billion in the Philippines since 2010. The expansion adds to the country's existing manufacturing and export role within PMI's international supply chain.
company
Nov.16
U.S. Rep. Krishnamoorthi Questions FDA Over Planned PMTA Rewrite, Seeks Communications With Altria and Reynolds
U.S. Rep. Krishnamoorthi Questions FDA Over Planned PMTA Rewrite, Seeks Communications With Altria and Reynolds
U.S. Rep. Raja Krishnamoorthi on Oct. 6 questioned the FDA over its plan to reassess and potentially replace the 2021 PMTA regulatory framework, asking the agency to identify provisions it may change or eliminate, state whether current scientific evidentiary standards will be maintained, and disclose communications with Altria, Reynolds and other parties challenging the rule. Krishnamoorthi led a congressional investigation into JUUL and youth vaping in 2019 and has since remained active on e-cigarette regulation and enforcement.
Regulations
Oct.08
Malaysia Reviews Possible Refund of $92 Million in Vape Taxes After Court Rules 2023 Nicotine Exemption Unlawful
Malaysia Reviews Possible Refund of $92 Million in Vape Taxes After Court Rules 2023 Nicotine Exemption Unlawful
Malaysia's Ministry of Finance said in a written parliamentary reply on November 17, 2026, that it was examining whether a court ruling concerning the country's 2023 liquid-nicotine exemption affected the legal basis for vape excise duties already collected. Royal Malaysian Customs Department records show that the government has collected RM377.08 million (approximately $92 million) in vape-related excise duties since May 2023, with the proceeds transferred to the federal Consolidated Fund. In May, the Kuala Lumpur High Court ruled that the 2023 decision to exempt liquid and gel nicotine used in vaping products from the Poisons List was unlawful. The government withdrew its appeal in August but has not decided whether the taxes should be refunded. The Finance Ministry is also seeking the Health Ministry's position on future vaping regulation.
Regulations
Nov.19
Product | Philip Morris Korea Launches Two TEREA ONYX Capsule Tobacco Sticks, Expanding Portfolio to Five Lines
Product | Philip Morris Korea Launches Two TEREA ONYX Capsule Tobacco Sticks, Expanding Portfolio to Five Lines
Philip Morris Korea launched TEREA ONYX, a new tobacco stick line for IQOS ILUMA devices, on October 15, 2026. The initial products, AMANG PEARL and CALI PEARL, feature tropical-inspired flavors, Fresh Filters and capsules designed to deliver different flavor experiences before and after activation. Both are priced at KRW 4,800 per pack and are available at convenience stores nationwide and IQOS-operated stores in South Korea. The launch expands the Korean TEREA portfolio from four product lines to five, following earlier capsule tobacco stick additions in 2026.
product
Oct.23
2Firsts Data|China’s Vape-Related Exports Rose 3.3% in August 2026 as UK Shipments Jumped 51.4% and U.S. Exports Fell 12.4%
2Firsts Data|China’s Vape-Related Exports Rose 3.3% in August 2026 as UK Shipments Jumped 51.4% and U.S. Exports Fell 12.4%
China exported $979 million of vape-related products in August 2026, up 3.3% from a year earlier but down 6.4% from July. The UK replaced the U.S. as the main source of growth: UK-bound shipments jumped 51.4% to a 2026 high of $177 million, while exports to the U.S. fell 12.4% to $339 million. Shipments to markets outside the U.S. increased 14.2%, broadening growth beyond the market that had driven July’s rebound.
News
Sep.23 by 2Firsts Perspectives
Iowa Sets November 16 Vape Directory Launch: Unlisted Products Face Sales Ban, Manufacturers $1,000 Daily Fines per Product
Iowa Sets November 16 Vape Directory Launch: Unlisted Products Face Sales Ban, Manufacturers $1,000 Daily Fines per Product
Iowa plans to publish its first vapor products directory on November 16, 2026, after which products not listed will be prohibited from sale or offer for sale in the state. The Department of Revenue expects to begin penalty enforcement on December 17, following an initial 21-business-day period focused on compliance education. Under House File 2677, retailers, distributors and wholesalers selling unlisted products face civil penalties of $300 per product per day, while manufacturers face $1,000 per product per day. Eligibility extends to FDA-authorized products and certain products meeting historical marketing and pending PMTA requirements. The directory program resumed after a federal appeals court vacated a preliminary injunction in July 2026.
Regulations
Nov.05